Form of Proxy

Election of Director to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.

Election of Director to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.

Election of Director to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.

Election of Director to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer

Election of Director to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.

Election of Director to serve for the next year and until their successors are elected and qualified: Harish Manwani

Election of Director to serve for the next year and until their successors are elected and qualified: Daniel P. ODay

Election of Director to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez

Election of Director to serve for the next year and until their successors are elected and qualified: Anthony Welters

To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.

To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.

To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.

To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.

To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.